Moderna strengthens its Swiss ties after doing business in Japan. The biotechnology company has announced a new supply agreement with the Swiss federal government of seven million doses of the Covid-19 booster vaccine.
Delivery of these doses is scheduled for 2023 and includes an additional purchase option for seven million doses for delivery in 2023 and 2024. These vaccines are in addition to the seven million doses to be delivered to Switzerland during the second half of 2022. The Government of the Swiss country exercised its purchase option in December 2021.
“Booster doses will continue to be critical to keeping infection rates low in our communities as we continue our fight against the pandemic,” said Stéphane Bancel, CEO of Moderna.
Swissmedic has granted approval to Spikevax, an elastomeric mRNA vaccine, indicated for active immunization to prevent coronavirus disease in persons twelve years of age and older.
Last week, the US biotech company announced an agreement with the Japanese Ministry of Health, Labor and Welfare to supply the country seventy million additional doses of the booster vaccine against Covid-19.
The vaccine is indicated for immunization in persons twelve years of age and older.
This agreement is subject to the Japanese Ministry of Health securing a budget for the additional supply. For this year, The Japanese Government has contracted 93 million doses of the Moderna vaccine.
In the ten years since its inception, Moderna has transformed from a research-stage company advancing programs in the mRNA field to a company with a diverse portfolio of vaccines and therapeutics in seven modalities, a broad portfolio of intellectual property in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing facility that enables rapid clinical and commercial-scale production.
–
